Featured
-
-
News & Views |
The path to retinoblastoma
Genomic analyses of tumours of the childhood cancer retinoblastoma reveal a low mutation rate, challenging the view that genomic instability is crucial for its progression. The work also identifies a new therapeutic target. See Article p.329
- Julien Sage
- & Michael L. Cleary
-
Article
| Open AccessA novel retinoblastoma therapy from genomic and epigenetic analyses
The retinoblastoma genome is shown to be stable, but multiple cancer pathways are identified that are epigenetically deregulated, providing potential new therapeutic targets.
- Jinghui Zhang
- , Claudia A. Benavente
- & Michael A. Dyer
-
Autumn Books |
Neuroscience: Learning to see
Steve Silberman is moved by Oliver Sacks's poignant account of losing his vision through cancer.
- Steve Silberman
-
Letter |
NRMT is an α-N-methyltransferase that methylates RCC1 and retinoblastoma protein
α-N-methylation is an unusual post-translational modification in which the amino-terminal residues of proteins are methylated. One example is the Ran guanine nucleotide-exchange factor, RCC1, which requires methylation for its association with chromatin. These authors describe the first α-N-methyltransferase, named N-terminal RCC1 methyltransferase (NRMT). They identify the NRMT recognition sequence and several new methylation targets, and demonstrate the importance of α-N-methylation for normal bipolar spindle formation and chromosome segregation.
- Christine E. Schaner Tooley
- , Janusz J. Petkowski
- & Ian G. Macara